The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia

Se Ryeon Lee, Deok Hwan Yang, Jae Sook Ahn, Yeo Kyeoung Kim, Je Jung Lee, Young Jin Choi, Ho Jin Shin, Joo Seop Chung, Yoon Young Cho, Yee Soo Chae, Jong Gwang Kim, Sang Kyun Sohn, Hyeoung Joon Kim

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A refractory and resistant disease to conventional induction chemotherapy and relapsed disease are considered as the most important adverse prognostic factors for acute myeloid leukemia (AML). Sixty-one patients (median age, 33.6 yr) with relapsed or refractory AML were treated with the FLAG regimen that consisted of fludarabine (30 mg/m2, days 1-5), cytarabine (2.0 g/m2, days 1-5) and granulocyte colony-stimulating factor. Of the treated patients 29 patients (47.5%) achieved complete remission (CR). Higher CR rates were observed for patients with a first or second relapse as compared to patients with a primary refractory response or relapse after stem cell transplantation (HSCT). There was a significant difference in the response rates according to the duration of leukemia-free survival (pre-LFS) before chemotherapy (P=0.05). The recovery time of both neutrophils (≥500/μL) and platelets (≥20,000/μL) required a median of 21 and 18 days, respectively. Treatment-related mortality (TRM) occurred in seven patients (11.4%), of which 71.4% of TRM was caused by an invasive aspergillosis infection. After achieving CR, 18 patients underwent consolidation chemotherapy and six patients underwent allogeneic HSCT. In conclusion, FLAG chemotherapy without idarubicin is a relatively effective and well-tolerated regimen for relapsed or refractory AML and the use of FLAG chemotherapy has allowed intensive post-remission therapy including HSCT.

Original languageEnglish
Pages (from-to)498-503
Number of pages6
JournalJournal of Korean Medical Science
Volume24
Issue number3
DOIs
Publication statusPublished - 2009 Jun 1
Externally publishedYes

Fingerprint

Idarubicin
Acute Myeloid Leukemia
Drug Therapy
Consolidation Chemotherapy
Recurrence
Induction Chemotherapy
Aspergillosis
Mortality
Cytarabine
Stem Cell Transplantation
Granulocyte Colony-Stimulating Factor
Leukemia
Neutrophils
Therapeutics
Blood Platelets
Survival

Keywords

  • Acute
  • FLAG Chemotherapy
  • Leukemia
  • Myeloid
  • Toxicity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia. / Lee, Se Ryeon; Yang, Deok Hwan; Ahn, Jae Sook; Kim, Yeo Kyeoung; Lee, Je Jung; Choi, Young Jin; Shin, Ho Jin; Chung, Joo Seop; Cho, Yoon Young; Chae, Yee Soo; Kim, Jong Gwang; Sohn, Sang Kyun; Kim, Hyeoung Joon.

In: Journal of Korean Medical Science, Vol. 24, No. 3, 01.06.2009, p. 498-503.

Research output: Contribution to journalArticle

Lee, SR, Yang, DH, Ahn, JS, Kim, YK, Lee, JJ, Choi, YJ, Shin, HJ, Chung, JS, Cho, YY, Chae, YS, Kim, JG, Sohn, SK & Kim, HJ 2009, 'The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia', Journal of Korean Medical Science, vol. 24, no. 3, pp. 498-503. https://doi.org/10.3346/jkms.2009.24.3.498
Lee, Se Ryeon ; Yang, Deok Hwan ; Ahn, Jae Sook ; Kim, Yeo Kyeoung ; Lee, Je Jung ; Choi, Young Jin ; Shin, Ho Jin ; Chung, Joo Seop ; Cho, Yoon Young ; Chae, Yee Soo ; Kim, Jong Gwang ; Sohn, Sang Kyun ; Kim, Hyeoung Joon. / The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia. In: Journal of Korean Medical Science. 2009 ; Vol. 24, No. 3. pp. 498-503.
@article{65e4b88463aa4bb09a76f32244219a79,
title = "The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia",
abstract = "A refractory and resistant disease to conventional induction chemotherapy and relapsed disease are considered as the most important adverse prognostic factors for acute myeloid leukemia (AML). Sixty-one patients (median age, 33.6 yr) with relapsed or refractory AML were treated with the FLAG regimen that consisted of fludarabine (30 mg/m2, days 1-5), cytarabine (2.0 g/m2, days 1-5) and granulocyte colony-stimulating factor. Of the treated patients 29 patients (47.5{\%}) achieved complete remission (CR). Higher CR rates were observed for patients with a first or second relapse as compared to patients with a primary refractory response or relapse after stem cell transplantation (HSCT). There was a significant difference in the response rates according to the duration of leukemia-free survival (pre-LFS) before chemotherapy (P=0.05). The recovery time of both neutrophils (≥500/μL) and platelets (≥20,000/μL) required a median of 21 and 18 days, respectively. Treatment-related mortality (TRM) occurred in seven patients (11.4{\%}), of which 71.4{\%} of TRM was caused by an invasive aspergillosis infection. After achieving CR, 18 patients underwent consolidation chemotherapy and six patients underwent allogeneic HSCT. In conclusion, FLAG chemotherapy without idarubicin is a relatively effective and well-tolerated regimen for relapsed or refractory AML and the use of FLAG chemotherapy has allowed intensive post-remission therapy including HSCT.",
keywords = "Acute, FLAG Chemotherapy, Leukemia, Myeloid, Toxicity",
author = "Lee, {Se Ryeon} and Yang, {Deok Hwan} and Ahn, {Jae Sook} and Kim, {Yeo Kyeoung} and Lee, {Je Jung} and Choi, {Young Jin} and Shin, {Ho Jin} and Chung, {Joo Seop} and Cho, {Yoon Young} and Chae, {Yee Soo} and Kim, {Jong Gwang} and Sohn, {Sang Kyun} and Kim, {Hyeoung Joon}",
year = "2009",
month = "6",
day = "1",
doi = "10.3346/jkms.2009.24.3.498",
language = "English",
volume = "24",
pages = "498--503",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "3",

}

TY - JOUR

T1 - The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia

AU - Lee, Se Ryeon

AU - Yang, Deok Hwan

AU - Ahn, Jae Sook

AU - Kim, Yeo Kyeoung

AU - Lee, Je Jung

AU - Choi, Young Jin

AU - Shin, Ho Jin

AU - Chung, Joo Seop

AU - Cho, Yoon Young

AU - Chae, Yee Soo

AU - Kim, Jong Gwang

AU - Sohn, Sang Kyun

AU - Kim, Hyeoung Joon

PY - 2009/6/1

Y1 - 2009/6/1

N2 - A refractory and resistant disease to conventional induction chemotherapy and relapsed disease are considered as the most important adverse prognostic factors for acute myeloid leukemia (AML). Sixty-one patients (median age, 33.6 yr) with relapsed or refractory AML were treated with the FLAG regimen that consisted of fludarabine (30 mg/m2, days 1-5), cytarabine (2.0 g/m2, days 1-5) and granulocyte colony-stimulating factor. Of the treated patients 29 patients (47.5%) achieved complete remission (CR). Higher CR rates were observed for patients with a first or second relapse as compared to patients with a primary refractory response or relapse after stem cell transplantation (HSCT). There was a significant difference in the response rates according to the duration of leukemia-free survival (pre-LFS) before chemotherapy (P=0.05). The recovery time of both neutrophils (≥500/μL) and platelets (≥20,000/μL) required a median of 21 and 18 days, respectively. Treatment-related mortality (TRM) occurred in seven patients (11.4%), of which 71.4% of TRM was caused by an invasive aspergillosis infection. After achieving CR, 18 patients underwent consolidation chemotherapy and six patients underwent allogeneic HSCT. In conclusion, FLAG chemotherapy without idarubicin is a relatively effective and well-tolerated regimen for relapsed or refractory AML and the use of FLAG chemotherapy has allowed intensive post-remission therapy including HSCT.

AB - A refractory and resistant disease to conventional induction chemotherapy and relapsed disease are considered as the most important adverse prognostic factors for acute myeloid leukemia (AML). Sixty-one patients (median age, 33.6 yr) with relapsed or refractory AML were treated with the FLAG regimen that consisted of fludarabine (30 mg/m2, days 1-5), cytarabine (2.0 g/m2, days 1-5) and granulocyte colony-stimulating factor. Of the treated patients 29 patients (47.5%) achieved complete remission (CR). Higher CR rates were observed for patients with a first or second relapse as compared to patients with a primary refractory response or relapse after stem cell transplantation (HSCT). There was a significant difference in the response rates according to the duration of leukemia-free survival (pre-LFS) before chemotherapy (P=0.05). The recovery time of both neutrophils (≥500/μL) and platelets (≥20,000/μL) required a median of 21 and 18 days, respectively. Treatment-related mortality (TRM) occurred in seven patients (11.4%), of which 71.4% of TRM was caused by an invasive aspergillosis infection. After achieving CR, 18 patients underwent consolidation chemotherapy and six patients underwent allogeneic HSCT. In conclusion, FLAG chemotherapy without idarubicin is a relatively effective and well-tolerated regimen for relapsed or refractory AML and the use of FLAG chemotherapy has allowed intensive post-remission therapy including HSCT.

KW - Acute

KW - FLAG Chemotherapy

KW - Leukemia

KW - Myeloid

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=67649158524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649158524&partnerID=8YFLogxK

U2 - 10.3346/jkms.2009.24.3.498

DO - 10.3346/jkms.2009.24.3.498

M3 - Article

C2 - 19543516

AN - SCOPUS:67649158524

VL - 24

SP - 498

EP - 503

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 3

ER -